CoChat

Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

Open access
Raz, Itamar · 2013 · Diabetes Care

The DOI matches its Crossref record; 61 of the 66 references it cites were found in a registry or an index.

Abstract

oth the prevalence and incidence of type 2 diabetes are increasing worldwide in conjunction with increased Westernization of the population's lifestyle.Type 2 diabetes is still a leading cause of cardiovascular disease (CVD), amputation, renal failure, and blindness.The risk for microvascular complications is related to overall glycemic burden over time as measured by A1C (1,2).The UK Prospective Diabetes Study (UKPDS) 10-year follow-up demonstrated a possible effect on CVD as well (3).A meta-analysis of cardiovascular outcome in patients with long disease duration including Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE), and Veterans Affairs Diabetes Trial (VADT) suggested that in these populations the reduction of ~1% in A1C is associated with a 15% relative reduction in nonfatal myocardial infarction (4).Most antihyperglycemic drugs besides insulin reduce A1C values to similar levels (5) but differ in their safety elements and pathophysiological effect.Thus, there is a need for recommending a drug therapy preference.While the positive effects on prevention of microvascular complications were demonstrated with the various antihyperglycemic drugs (1,2,6,7), several questions are left open regarding this therapy in newly diagnosed type 2 diabetes:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dcs13-2035

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. First, set your target A1C (8). If not at target, stage 1: Start with lifestyle and metformin. If A1C ≥7.5% (10) or ≥9% (9,10), consider short-term combination therapy or insulin, respectively. Stage 2: If A1C is not at target after 3–6 months of metformin therapy, suggest adding incretin therapy (in relation to BMI). For patients resistant to GLP-1 therapy with BMI >35 kg/m2 who do not reach target, consider bariatric surgery or proceed to stage 3. Stage 3: If not yet at target, recommend adding a basal insulin analog—mainly in patients with high fasting or preprandial glucose—and pioglitazone, sulfonylurea (SU)/glinides, or rapid/premix insulin in cases of postprandial hyperglycemia.
Figure 1 Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. First, set your target A1C (8). If not at target, stage 1: Start with lifestyle and metformin. If A1C ≥7.5% (10) or ≥9% (9,10), consider short-term combination therapy or insulin, respectively. Stage 2: If A1C is not at target after 3–6 months of metformin therapy, suggest adding incretin therapy (in relation to BMI). For patients resistant to GLP-1 therapy with BMI >35 kg/m2 who do not reach target, consider bariatric surgery or proceed to stage 3. Stage 3: If not yet at target, recommend adding a basal insulin analog—mainly in patients with high fasting or preprandial glucose—and pioglitazone, sulfonylurea (SU)/glinides, or rapid/premix insulin in cases of postprandial hyperglycemia.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

Metadata

Authors
Raz, I.
Affiliations
Hadassah Medical Center (IL)
Corresponding author
Raz, Itamar
Venue
Diabetes Care
Published
2013-07-17
Volume
36
Issue
Supplement_2
Pages
S139-S144
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2087910657
Cited by
71
References
66
Citations by year
2026: 4 · 2025: 3 · 2024: 7 · 2023: 2 · 2022: 3 · 2021: 7 · 2020: 3 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 6 · 2014: 11 · 2013: 1
FWCI
6.55
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, newly diagnosed diabetes, antidiabetic drugs, glycemic control, HbA1c, cardiovascular risk, microvascular complications, drug therapy selection, treatment guidelines
MeSH terms
Algorithms, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Practice Guidelines as Topic, Guideline Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.